Human IL-7 Protein, premium grade
分子別名(Synonym)
IL7,Interleukin-7
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-7, premium grade (IL7-H4219) is expressed from human 293 cells (HEK293). It contains AA Asp 26 - His 177 (Accession # P13232-1).
Predicted N-terminus: Asp 26
重組人IL-7蛋白,premium級(IL7-H4219),專為臨床前階段設(shè)計,具有與GMP級重組人IL-7蛋白(GMP-L07H24)相同的活性和性能,可實(shí)現(xiàn)從臨床前開發(fā)到臨床階段的無縫過渡。在原材料安全不是首要任務(wù)的早期開發(fā)階段,premium產(chǎn)品為GMP級產(chǎn)品提供了一種經(jīng)濟(jì)高效的替代品。通過在早期開發(fā)階段使用Premium級產(chǎn)品,您可以輕松過渡到臨床和商業(yè)階段,而無需重新驗(yàn)證原材料和修改制造工藝。
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 17.4 kDa. The protein migrates as 23 kDa and 28 kDa (±3 kDa) when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白殘留(Host Cell Protein)
<0.5 ng/μg of protein tested by ELISA.
宿主核酸殘留(Host Cell DNA)
<0.02 ng/μg of protein tested by DNA Fluorescent Staining method.
無菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素7也稱為IL-7,是紅骨髓和胸腺中基質(zhì)細(xì)胞分泌的造血生長因子。它也由角質(zhì)形成細(xì)胞、樹突細(xì)胞、肝細(xì)胞、神經(jīng)元和上皮細(xì)胞產(chǎn)生,但不是由淋巴細(xì)胞產(chǎn)生的。IL-7刺激多能造血干細(xì)胞分化為淋巴祖細(xì)胞,它還刺激淋巴譜系中所有細(xì)胞(B細(xì)胞、T細(xì)胞和NK細(xì)胞)的增殖。在B細(xì)胞成熟、T細(xì)胞和NK細(xì)胞存活、發(fā)育和穩(wěn)態(tài)的某些階段,它對增殖很重要。IL-7是一種對B和T細(xì)胞發(fā)育很重要的細(xì)胞因子。這種細(xì)胞因子和肝細(xì)胞生長因子(HGF)形成異二聚體,作為前B細(xì)胞生長刺激因子發(fā)揮作用。IL-7與IL-7受體結(jié)合,IL-7受體是由白細(xì)胞介素-7受體α和普通γ鏈?zhǔn)荏w組成的異二聚體。Il-7促進(jìn)血液系統(tǒng)惡性腫瘤(急性淋巴細(xì)胞白血病、T細(xì)胞淋巴瘤)。在HIV感染患者的血漿中也檢測到IL-7水平升高。IL-7作為一種免疫治療劑已在許多臨床前動物研究中進(jìn)行了研究,最近在各種惡性腫瘤和HIV感染期間的人類臨床試驗(yàn)中也進(jìn)行了研究。IL-7也可能有利于改善同種異體干細(xì)胞移植后的免疫恢復(fù)。
關(guān)鍵字: IL-7;IL-7蛋白;IL-7重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。